Arcadia Biosciences Q3 net income attributable to common stockholders more than doubles to $1.76 million
PUBT · 1d ago
Share
Listen to the news
- Arcadia Biosciences’ third-quarter 2026 net income attributable to common stockholders more than doubled year-over-year to $1.76 million.
- Total revenues rose 24% year-over-year to $1.62 million, driven by strong volumes from summer programs.
- For the first nine months of 2026, net loss attributable to common stockholders widened year-over-year to $8.9 million.
- Zola Espresso shipments begin in November 2026, with slim-can varieties set to launch in the first half of 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcadia Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121605PRIMZONEFULLFEED9876157) on November 12, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending